We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Conflict Should DQ Katten In IP Row, Valeant Tells Fed. Circ.

Law360, Washington (September 12, 2018, 7:26 PM EDT) -- Katten Muchin Rosenman LLP should be disqualified from three ongoing drug patent appeals, Valeant Pharmaceuticals International Inc. told a Federal Circuit panel Wednesday, arguing that when the firm hired two Alston...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.